コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 CMO included only symptom-palliation, whereas nonoperati
2 CMO patients had 98% 30-day mortality.
10 f magnitude faster than the state-of-the-art CMO solvers Apurva, MSVNS and AlEigen7, and its similari
11 issues that were presented and discussed at CMO and proposes some steps that could be taken to impro
13 had aggressive initial management and became CMO following in-hospital complications of their care.
18 hemical sensor based on very low-dimensional CMO NPs/GCE using electrochemical reduction phenomena.
19 parous group, 21% had cystoid macular edema (CMO) requiring treatment and 46% had cataracts or were p
20 tters or better); (2) cystoid macular edema (CMO), foveal thickness, and macular volume; (3) developm
22 lar to the pivotal trials of aflibercept for CMO secondary to CRVO, which used monthly and then as-ne
25 Consequently, the surface-hydrogenated GaN@CMO-H illustrates a considerable ethylene production act
26 CrMnO(x) is coupled with GaN nanowires (GaN@CMO-H) for light-driven ethanol dehydration to ethylene.
28 AMI across 827 hospitals, 13 955 (2.9%) had CMO status at discharge (2.6% non-ST-segment-elevation m
31 with higher VAS scores, whereas increases in CMO (B = -0.011, p < 0.001) were associated with lower V
32 uggests that there is a greater reduction in CMO observed at 6 months in vitrectomized eyes treated w
36 ., Chenopodiaceae) probe was used to isolate CMO cDNAs from sugar beet (Beta vulgaris L., Chenopodiac
38 ncorporation of the human lymphoid cell line CMO, which exhibits constitutive activation of the STAT5
39 initially managed invasively but later made CMO experienced high rates of procedural complications,
40 salinization (NaCl:CaCl2 = 5.7:1, mol/mol), CMO mRNA, protein, and enzyme levels in leaves increased
42 step is catalyzed by choline monooxygenase (CMO), a ferredoxin-dependent stromal enzyme that has bee
45 9 +/- 31 mum at 16 weeks; whereas in the non-CMO group, macular thickness showed a slight increase of
46 o 0.66 +/- 0.41 at week 16; while in the non-CMO group, mean BCVA improved markedly from 0.98 +/- 0.5
47 s of LLS1(PAO), CAO, TIC55 and PTC52 but not CMO are found in the genomes of several cyanobacteria.
48 o report the rate of cystoid macular oedema (CMO) as detected by spectral-domain optical coherence to
49 l of aflibercept for cystoid macular oedema (CMO) secondary to central retinal vein occlusion (CRVO).
53 oblot analyses showed that the expression of CMO in leaves increased several-fold during salinization
54 de (GCE) was fabricated with a thin-layer of CMO NPs by conducting coating binders for the developmen
55 er content declined to 59% and the levels of CMO mRNA, protein, and enzyme activity rose 3- to 5-fold
57 morphological, and structural properties of CMO NPs were characterized in details using FT-IR, UV/vi
58 tes across hospitals, with the proportion of CMO patients ranging from 0% to 17.1% and a median odds
61 y treatment modality: comfort measures only (CMO), nonoperative treatment, or operative intervention.
62 xt pandemic, the Clinical Microbiology Open (CMO) assembled key stakeholders including directors of c
65 for Microbiology Clinical Microbiology Open (CMO) with various stakeholders to identify potential sol
67 ein structures, maximum Contact Map Overlap (CMO) has received sustained attention during the past de
68 A key composition is cobalt (Co)-Mn oxide (CMO) spinel, Co(x)Mn(3-x)O(4), that, despite exemplary p
69 esis is catalyzed by choline mono-oxygenase (CMO), a stromal enzyme with a Rieske-type [2Fe-2S] cente
73 outcome was meeting the minimum recommended (CMO, UK) 5 x 30 mins moderate physical activity per week
76 nthetic method for small, colloidally stable CMO spinel nanocrystals with tunable composition and low
84 d appropriate transition of such patients to CMO, if aligned with their values, remain important area
85 rative efforts discussed during the past two CMO meetings proved critical in addressing the COVID-19
90 dent patient characteristics associated with CMO status included male gender, White race, nonprivate